Transcriptomics in cancer is one of the newly researched domains because it mirrors all the post genomic variation.
In spite of extended studies, carcinogenesis still remains a highly unknown process due to multiple factors that are
involved in cancer initiation. Carcinogenesis is a complex network of processes starting from genetic alterations, accumulation
of mutation, going through epigenetic alteration and ending with proteomic alterations that can lead to uncontrolled
proliferation, differentiation, invasion, and ultimately metastasis. From gene to protein, cancer cells can be studied at transcriptomic
level in order to detect new relevant biomarkers and/or new drug targets. We highlight herein some of the cancers
that were lately subjects for transcriptomic biomarkers patents, among which: breast, prostate, oral, brain, pancreatic
cancer and cutaneous melanoma. A glimpse of the up-dated methodology and analysis used in transcriptomics is presented
along with the recent patents that claim transcriptomics biomarkers.